Medicare AdvantageCoverageMedium impact
MA07.041c, Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies
Independence Blue Cross·Oncology, Radiology, Radiation Oncology·Pharmacy
Effective date
Oct 29, 2025
We identified it
Jun 19, 2026
Summary
MA07.041c policy regarding Drug-Eluting Beads and Bland Embolization for hepatic malignancies was reissued effective 10/29/2025 with revisions posted 03/27/2026. This recent policy change establishes or clarifies Medicare Advantage coverage criteria, prior authorization requirements, and billing guidelines for interventional embolization procedures treating liver cancers. The billing team must review coverage limitations, medical necessity documentation requirements, and applicable procedure codes to ensure compliant claims submission.
Action Required
By 04/30/2026: Billing team must obtain and review the complete MA07.041c policy text from the source URL to identify specific CPT/HCPCS codes, prior authorization requirements, and documentation mandates for drug-eluting bead and bland embolization procedures. Update billing system with any new prior authorization rules and communicate coverage criteria to providers and clinical staff. Ensure all claims for hepatic malignancy embolization procedures submitted after 10/29/2025 comply with revised coverage and documentation standards. Claims submitted without required prior authorization or documentation may be denied.